Announced
Completed
VERONA PHARMA PLC / VIVO CAPITAL LLC / NOVO A/S / Acquisition / Acquisition / Public / £6m
Financials
Transaction Value£6m
Consideration Type-
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-
Sources
Tags
inflammatory
chronic respiratory
hay fever
therapeutic drugs
development
Pharmaceuticals
United Kingdom
Acquisition
Public
Completed
Single Bidder
Private Equity
Synopsis
PIPE investment by Novo and Vivo Capital in Verona Pharma, a developer of therapeutic drug treatments for hay fever and other chronic respiratory and inflammatory diseases.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.